Extracellular vesicles

Therapeutic Potential of Bioactive Compounds in Edible Mushroom-Derived Extracellular Vesicles: Isolation and Characterization of EVs from Pleurotus eryngii

mycolabadmin

Researchers isolated tiny particles called extracellular vesicles (EVs) from a medicinal mushroom called king oyster mushroom (Pleurotus eryngii). These EVs act like natural delivery packages containing beneficial compounds like antioxidants and anti-inflammatory molecules. The study found that EVs from mushroom mycelium (the root-like part) were purer and more potent than those from the mushroom cap, with strong abilities to neutralize harmful free radicals in the body.

Therapeutic Potential of Bioactive Compounds in Edible Mushroom-Derived Extracellular Vesicles: Isolation and Characterization of EVs from Pleurotus eryngii

mycolabadmin

Scientists have isolated and studied tiny capsule-like particles called extracellular vesicles from the oyster mushroom Pleurotus eryngii. These vesicles, which are naturally produced by the mushroom, contain beneficial compounds like antioxidants that help protect cells from damage. The researchers found that vesicles from mushroom mycelium (the root-like part) were of higher quality and had stronger antioxidant effects than those from the fruiting body. These findings suggest that mushroom-derived vesicles could potentially be developed into health supplements or therapeutic treatments.

Stage-Specific Lipidomes of Gastrodia elata Extracellular Vesicles Modulate Fungal Symbiosis

mycolabadmin

Researchers studied how a special orchid called Gastrodia elata communicates with its fungal partner Armillaria. They found that tiny fat-like packages called extracellular vesicles carry specific molecules that help the orchid and fungus work together. These special molecules, including compounds like 7,8-dehydroastaxanthin, are most abundant when the orchid is actively absorbing nutrients from the fungus.

Things you wanted to know about fungal extracellular vesicles (but were afraid to ask)

mycolabadmin

Fungal extracellular vesicles are tiny particles released by fungal cells that play important roles in how fungi cause disease and how our immune system responds. These particles can either help fight infections or make them worse depending on the type of fungus and conditions involved. Scientists are discovering that these vesicles could potentially be used as vaccines and may explain why some antifungal drugs stop working.

Unveiling microRNA-like small RNAs implicated in the initial infection of Fusarium oxysporum f. sp. cubense through small RNA sequencing

mycolabadmin

Researchers discovered specific small RNA molecules produced by the fungus that causes banana wilt disease. These molecular signals, particularly one called milR106, are critical for the fungus’s ability to infect and damage banana plants. By understanding how these molecules work, scientists can develop better strategies to protect banana crops from this devastating disease that threatens global banana production.

Biocontrol of Root-Knot Nematodes via siRNA-Loaded Extracellular Vesicles From a Nematophagous Fungus Arthrobotrys oligospora

mycolabadmin

Scientists developed a new way to control harmful root-knot nematodes that damage crops by using natural containers called extracellular vesicles from a fungus. These vesicles carry small RNA molecules that silence genes essential for nematode survival and reproduction. When tested on tomato plants, this fungal-based treatment reduced nematode damage by about 60% while promoting healthier plant growth, offering an eco-friendly alternative to chemical pesticides.

Things you wanted to know about fungal extracellular vesicles (but were afraid to ask)

mycolabadmin

Fungal extracellular vesicles (EVs) are tiny packages released by fungal cells that play important roles in fungal infections and how our immune system responds to them. Scientists have confirmed these EVs are real biological structures, not laboratory artifacts, and discovered they are produced by many different fungal species. Interestingly, these EVs can have opposite effects on the immune system depending on the fungus involved—sometimes helping our bodies fight infection and sometimes making infections worse, making them both potential vaccines and virulence factors.

Vesicle inhibition reduces Candida biofilm resistance

mycolabadmin

Researchers found that common FDA-approved drugs designed to block vesicle production in human cells can also reduce the protective matrix that Candida fungus builds around itself in biofilms. By combining these vesicle-blocking drugs with the antifungal fluconazole, the scientists were able to kill biofilm-forming Candida more effectively than either treatment alone. This discovery suggests a new approach to treating stubborn fungal infections on medical devices like catheters, potentially eliminating the need to surgically remove infected equipment.

The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release

mycolabadmin

Researchers discovered that a small peptide derived from a bacterium called EntV can fight Candida fungal infections by targeting specialized vesicles (tiny sacs) that fungi use to spread infections. Unlike traditional antifungal drugs that kill fungi, EntV works by blocking the release of these vesicles, reducing the fungus’s ability to infect and form protective biofilms. This new approach could lead to treatments that work against drug-resistant fungi without the toxicity issues of current antifungals.

Research Keyword: Extracellular vesicles